StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP stock opened at $4.02 on Friday. The company’s fifty day simple moving average is $3.53 and its 200 day simple moving average is $4.34. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What is diluted earnings per share (Diluted EPS)?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Where to Find Earnings Call Transcripts
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
